Hi @GazBusey, very good questions mate. They definately seem to be targeting FA, and im not sure when the definative results will come through, but I, as well as you are very interested to see them. I was re-reading the results while between races at bathurst 1000. The study was heavily focused on FA. Regarding take over, if we can continue to show brilliant results, theres going to be ALOT of interest, eg. MSA, PD, Lewy body dementia, FA, than if ATH434 drastically reduces NfL as a whole such as recent results, it opens a MASSIVE cohort of potential other neurodegenerate diseases. And if that is the case this drug would be worth a significant amount, much larger than the FA by out. Regarding my initial email Q, ill post it below.
ATH Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)